MedTrace Logo

Antineoplastic Drugs in Elderly Patients

NCT05467189 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2022-07-20

No results posted yet for this study

Summary

The purpose is to study the population pharmacokinetics, effectiveness and safety of antineoplastic drugs (Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib, Imatinib, Lapatinib, etc) in elderly patients and recommend optimized dosage regimens.

Conditions

Interventions

DRUG

Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs)

As part of routine treatment.

Sponsors & Collaborators

  • Qianfoshan Hospital

    collaborator OTHER

  • The Second Hospital of Shandong University

    collaborator OTHER

  • The Affiliated Hospital of Qingdao University

    collaborator OTHER

  • Shandong University

    lead OTHER

Principal Investigators

  • Zhao Wei, Ph.D · Qianfoshan Hospital

Eligibility

Min Age
65 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2028-03-30
Completion
2028-06-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05467189 on ClinicalTrials.gov